Suzhen Wang

Key Laboratory Of Medicine And Health Of Shandong Province
Weifang, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.

Journal: International immunopharmacology

Published: November 18, 2022

Identification and Validation of RELN Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer.

Identification and Validation of RELN Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer.

Journal: Cells

Published: October 14, 2022

Bioinformatic analysis identifies the immunological profile of turner syndrome with different X chromosome origins.

Bioinformatic analysis identifies the immunological profile of turner syndrome with different X chromosome origins.

Journal: Frontiers in endocrinology

Published: August 21, 2022

HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer.

HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer.

Journal: Cancers

Published: June 06, 2022

Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations.

Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations.

Journal: NPJ precision oncology

Published: January 13, 2022

An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.

An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.

Journal: Cancer science

Published: November 23, 2021

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.

Journal: Frontiers in immunology

Published: October 20, 2021

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.

Journal: Cancer medicine

Published: October 07, 2021

Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.

Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.

Journal: Aging

Published: July 03, 2021

Immunological and clinical immunotherapy implications of NLRP3 mutations in melanoma.

Immunological and clinical immunotherapy implications of NLRP3 mutations in melanoma.

Journal: Aging

Published: June 17, 2021

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma.

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma.

Journal: Frontiers in immunology

Published: June 07, 2021

Assessing the Survival Benefit of Surgery and Various Types of Radiation Therapy for Treatment of Hepatocellular Carcinoma: Evidence from the Surveillance, Epidemiology, and End Results Registries.

Assessing the Survival Benefit of Surgery and Various Types of Radiation Therapy for Treatment of Hepatocellular Carcinoma: Evidence from the Surveillance, Epidemiology, and End Results Registries.

Journal: Journal of hepatocellular carcinoma

Published: July 19, 2020

Showing 1-12 of 18

Last Updated: 09/26/2026